Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE DE NOUES DE SIENNE : revenue, balance sheet and financial ratios

PHARMACIE DE NOUES DE SIENNE is a French company founded 8 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in NOUES DE SIENNE (14380), this company of category PME shows in 2020 a revenue of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE NOUES DE SIENNE (SIREN 831303763)
Indicator 2024 2023 2022 2021 2020 2019 2018
Revenue N/C N/C N/C N/C 1 884 918 € N/C N/C
Net income 175 538 € 205 879 € 281 070 € 312 520 € 256 731 € 278 288 € 248 193 €
EBITDA N/C N/C N/C N/C 290 959 € N/C N/C
Net margin N/C N/C N/C N/C 13.6% N/C N/C

Revenue and income statement

In 2024, PHARMACIE DE NOUES DE SIENNE generates positive net income of 176 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2024: 248 k€ -> 176 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

175 538 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 98%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 47%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

97.983%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

47.335%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

46.9%

Solvency indicators evolution
PHARMACIE DE NOUES DE SIENNE

Sector positioning

Debt ratio
97.98 2024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average -15 pts over 3 years

In 2024, the debt ratio of PHARMACIE DE NOUES DE SIENNE (97.98) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
47.34% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average +16 pts over 3 years

In 2024, the financial autonomy of PHARMACIE DE NOUES DE SIENNE (47.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 392.14. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

392.143

Liquidity indicators evolution
PHARMACIE DE NOUES DE SIENNE

Sector positioning

Liquidity ratio
392.14 2024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Excellent

In 2024, the liquidity ratio of PHARMACIE DE NOUES DE SIENNE (392.14) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE NOUES DE SIENNE

Positioning of PHARMACIE DE NOUES DE SIENNE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DE NOUES DE SIENNE is estimated at 2 450 640 € (range 1 706 587€ - 3 666 298€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1706k€ 2450k€ 3666k€
2 450 640 € Range: 1 706 587€ - 3 666 298€
NAF 5 année 2024

Valuation method used

Net Income Multiple
175 538 € × 14.0x = 2 450 640 €
Range: 1 706 587€ - 3 666 298€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE NOUES DE SIENNE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DE NOUES DE SIENNE

What is the revenue of PHARMACIE DE NOUES DE SIENNE ?

The revenue of PHARMACIE DE NOUES DE SIENNE in 2020 is 1.9 M€.

Is PHARMACIE DE NOUES DE SIENNE profitable?

Yes, PHARMACIE DE NOUES DE SIENNE generated a net profit of 176 k€ in 2024.

Where is the headquarters of PHARMACIE DE NOUES DE SIENNE ?

The headquarters of PHARMACIE DE NOUES DE SIENNE is located in NOUES DE SIENNE (14380), in the department Calvados.

Where to find the tax return of PHARMACIE DE NOUES DE SIENNE ?

The tax return of PHARMACIE DE NOUES DE SIENNE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE NOUES DE SIENNE operate?

PHARMACIE DE NOUES DE SIENNE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.